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World Health Organization estimated that heart failure initiated by coronary artery disease
and myocardial infarction (MI) leads to 29 per cent of deaths worldwide. Heart failure is one
of the leading causes of death in industrialized countries and is expected to become a global
epidemic within the twenty-ﬁrst century. MI, the main cause of heart failure, leads to a loss of
cardiac tissue impairment of left ventricular function. The damaged left ventricle undergoes
progressive ‘remodelling’ and chamber dilation, with myocyte slippage and ﬁbroblast prolifer-
ation. Repair of diseased myocardium with in vitro-engineered cardiac muscle patch/
injectable biopolymers with cells may become a viable option for heart failure patients.
These events reﬂect an apparent lack of effective intrinsic mechanism for myocardial repair
and regeneration. Motivated by the desire to develop minimally invasive procedures, the
last 10 years observed growing efforts to develop injectable biomaterials with and without
cells to treat cardiac failure. Biomaterials evaluated include alginate, ﬁbrin, collagen,
chitosan, self-assembling peptides, biopolymers and a range of synthetic hydrogels. The
ultimate goal in therapeutic cardiac tissue engineering is to generate biocompatible, non-
immunogenic heart muscle with morphological and functional properties similar to natural
myocardium to repair MI. This review summarizes the properties of biomaterial substrates
having sufﬁcient mechanical stability, which stimulates the native collagen ﬁbril structure
for differentiating pluripotent stem cells and mesenchymal stem cells into cardiomyocytes
for cardiac tissue engineering.
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1. INTRODUCTION
Cardiac tissue engineering promises to revolutionize the
treatment of patients with end-stage heart failure and
provides new solutions to the serious problems of
heart donor shortage. Heart disease is one of the most
common causes of death in the world [1]. Coronary
heart disease (CHD) and heart failure continue to be
signiﬁcant burdens to healthcare systems in the western
world. In the United States alone, there are 7.9 million
survivors of myocardial infarction (MI) and 16.8 million
people living with CHD (http://www.americanheart.
org). The single most common cause of left-sided car-
diac failure is ischaemic heart disease (also called
coronary artery disease) with an episode of acute MI.
Left ventricular dilatation is a well-recognized precursor
of ventricular dysfunction and congestive heart failure
after MI. The damaged left ventricle undergoes pro-
gressive ‘remodelling’ and chamber dilation, with
myocyte slippage and ﬁbroblast proliferation. The
impairment of heart wall muscle is permanent because,
after a massive cell loss owing to infarction, the myocar-
dial tissue lacks signiﬁcant intrinsic regenerative
capability to replace the lost cells. The enlargement in
ventricular volume leads to progressive structural and
functional changes in ventricles (called ventricular
remodelling). Ventricular remodelling is compensatory
at the initial stages, but adds further inefﬁciency to
the mechanical pumping of ventricular muscle, predis-
posing towards the ﬁnal stage of congestive heart
failure (CHF) [2], a condition in which the heart
cannot pump sufﬁcient amount of blood to meet the
metabolic requirements of the body.
Current therapeutic strategies to treat CHF are lim-
ited to surgical transplantation, coronary artery bypass
grafting (CABG), ventricular remodelling (resection),
dynamic latissimus dorsi (LD) cardiomyoplasty, cardiac
bioassist mechanical support and pharmacological inter-
vention. These treatment options have signiﬁcantly *Authors for correspondence (nnijrv@nus.edu.sg; seeram@nus.edu.sg).
J. R. Soc. Interface (2012) 9, 1–19
doi:10.1098/rsif.2011.0301
Published online 13 April 2011
Received 16 May 2011
Accepted 18 August 2011 1 This journal is q 2011 The Royal Societyimproved the quality of patient care, there are limitations
to each approach. Heart transplantation is traditionally
performed to treat intractable severe heart failure sec-
ondary to dilated and hypertrophic cardiomyopathy,
but its use is restricted by the shortage of donors. The
use of pluripotent stem cells to regenerate damaged
heart tissue is being advocated as the new treatment
for heart failure secondary to heart disease or severe MI.
Myocardial dysfunction resulting from atherosclerosis-
related MI is a widespread and important cause of
morbidity and mortality among adults. The adult mam-
malian heart has limited regenerative capacity and
therefore any signiﬁcant myocardial cell loss is mostly irre-
versible and may lead to progressive loss of ventricular
function and heart failure development. Despite the
improvements in several pharmacological and surgical
therapeutic measures, the prognosis for heart failure
patients remains poor. Cellular cardiomyoplasty seems
to reduce the size and ﬁbrosis of infarct scars, to limit
adverse post-ischaemic remodelling and to improve dias-
tolic function.
Restoration of cardiac function by replacing diseased
myocardium with functional cardiomyocytes (CMs) is an
intriguing strategy because it offers a potential cure.
Thereis anincreasingevidenceofexperimentalapproaches
to restore/regenerate failing myocardium. Two of the
promising pathways are direct implantation of primordial
type of cells into the injured heart and the replacement of
portions of heart muscle with tissue-engineered bio-
artiﬁcial grafts. Both the techniques display advantages
andlimitations.Thedevelopmentofabioartiﬁcialmyocar-
diumisanewchallenge;inthisapproach,tissue-engineered
procedures are associated with cell therapy. Organ decellu-
larization for bioscaffold fabrication is a new investigated
concept. Nanomaterials are emerging as the main candi-
dates in ensuring the achievement of a proper instructive
cellular niche with good drug release/administration prop-
erties [3]. Angiogenic cytokines can be used to induce
vascularization within a cardiac patch [4]. Steffens et al.
[5] physically immobilized vascular endothelial growth
factor (VEGF) onto heparinized collagen matrices.
The VEGF released from the matrices led to improved
endothelial cell proliferation and angiogenesis in the
chorioallantoic membrane. Alginate and alginate sulphate
scaffolds enhance cardiac patch vascularization and viabi-
lity by incorporating a mixture of prosurvival and
angiogenic factors (SDF, IGF-1 and VEGF) by afﬁnity
binding to the scaffold [6]. Collagen scaffolds with cova-
lently immobilized VEGF improved tissue formation by
promoting cell proliferation within the graft of both in
vitroandinvivo,thusleadingtoincreasedbloodvesselden-
sity and reduced construct thinning in a rat model of right
ventricle (RV)-free wall repair [7]. The direct transfer of
pluripotent stem cells into heart has been reported to
improve cardiac function of the recipient animals after
myocardial injury [8,9]. Limitations are arrhythmogeni-
city, immunogenicity and tumorigenicity of the injected
cells, as well as their insufﬁcient potential to survive,
engraft and differentiate into the cardiac cell phenotype.
The majority of previously developed bioartiﬁcial matrices
lack a heart-like microstructure. They are devoid of a vas-
cular tree or microvasculature and are destined to die
afterimplantationintotheischaemicheart.Thefunctional
improvement of the heart after cell or tissue transfer is
usually attributed to secondary angiogenesis because of
the lack of a convincing explanation of the mechanism of
engraftment and participation in contractile activity [10].
In the last few years, other strategies have been evolved,
aiming at restoring diseased areas of the heart. These
approaches include cellular transplantation, as well as in
vitro engineering of bioartiﬁcial myocardial tissues for
alleviation of MI.
2. MYOCARDIAL INFARCTION
MI results in the obstruction of blood supply to the heart
muscle that leads to substantial death of CMs in the
infarct zone followed by a rigorous inﬂammatory response
andremovalofdeadcellsbymarrow-derivedmacrophages
ormesenchymalstemcells(MSCs).Standardtreatmentof
this debilitating disease comprises pharmacological pro-
tection of the heart, either from a primary injury or from
secondary damage, as well as cardiovascular interven-
tions, including percutaneous transluminal coronary
angioplasty (PTCA) or heart transplantation. CMs are
themost physicallyenergeticcells inthebody,contracting
more than three billion times in an average human life-
span and pumping over 7000l of blood per day along
160000 km of blood vessels [11]. The control of heart
contractions is almost entirely self-contained and can be
attributed to the group of specialized CMs (pacemakers),
thefastestofwhicharelocatedinthemuscledrivenbythe
wavesofelectricalexcitationgeneratedbypacingcellsthat
spreadrapidlyalongthemembranesofadjoiningCMsand
triggerreleaseofcalcium,whichinturnstimulatecontrac-
tion of myoﬁbrils. Electromechanical coupling of
myocytes is crucial for their synchronous response to elec-
trical pacing signals [12]. According to theoretical
simulations, addition of a heart patch border zone could
decrease heart wall stress. In these simulations, added
materials are non-contractile and have stiffness up to 200
per cent of the average stiffness of passive myocardium.
The reduction in wall stress was calculated to be pro-
portional to the fractional volume added, with stiffer
materials improving this attenuation better [13]. On the
other hand, the stiffness of heart muscle is 10 kPa at the
beginning of diastole and 200–500 kPa at the end of dia-
stole [14,15]. Most studies support the conclusion that
cell implantation can improve contractile function of the
heart. Clinical studies are underway to investigate the
safety and feasibility of cell implantation in patients [16].
An alternative approach to deliver isolated cells into the
heartistouseatissueengineeringstrategy,inwhichasyn-
thetic biodegradable patch is populated in vitro with
MSCs and implanted onto the infarcted regions of MI
for cardiac tissue regeneration [17–20].
3. BIOMATERIAL STRATEGIES FOR
ALLEVIATION OF MYOCARDIAL
INFARCTION
3.1. Properties of biomaterials
Tissue engineering approaches are designed to repair
lost or damaged tissue through the use of growth fac-
tors, cellular transplantation, injectable biopolymers
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material approaches for the treatment of MI. The ﬁrst
involves polymeric left ventricular restraints in the pre-
vention of heart failure. The second uses in vitro-
engineered cardiac tissue, which is subsequently
implanted in vivo. The ﬁnal approach entails injecting
cells and/or a scaffold into the myocardium to create
in situ-engineered cardiac tissue. Tissue engineering
provides a solution to the problem of congenital
or acquired heart defects that can be used to replace or
reconstruct defective heart parts such as valves or
vessels. A fabricated tissue engineering scaffold should
be (i) highly porous with large interconnected pores (to
facilitate mass transport), (ii) hydrophilic (to enhance
cell attachment), (iii) structurally stable (to withstand
the shearing forces during bioreactor cultivation), (iv)
degradable (to provide ultimate biocompatibility of the
tissue graft), and (v) elastic (to enable transmission of
contractile forces) [21]. The biomaterial is used to
create an engineered myocardial patch that should be
easy to harvest, proliferate, non-immunogenic, and has
the ability to differentiate into mature, functional CMs.
Scaffold structure determines the transport of nutrients,
metabolites and regulatory molecules to and from the
cells, whereas the scaffold chemistry has an important
role in cell attachment and differentiation. Mechanical
properties of the scaffold should ideally match those of
the native tissue, providing mechanical integrity of the
forming tissue and supporting an in vivo-like mechano-
transduction between cells and their environment [11].
The ideal scaffold for implantation must meet several
stringent criteria for tissue engineering. It must be bio-
compatible, reactive to non-foreign body, resistant to
stress and strain, be sterilizable and match biomechani-
cal characteristics of tissue it is replacing. Material
degradation and resorption are other desirable proper-
ties, and the degradation products must be non-toxic
and readily eliminate from the body. From a macro-
scopic perspective, the scaffold should be porous, with
interconnecting pore structure to enable the accom-
modation of a large number of cells (CMs) and their
organization into a functioning tissue (ﬁgure 1). Pore
size of at least 50 mm is needed to allow the vasculariza-
tion of scaffold after transplantation, to supply the
seeded cells with nutrients and to remove secretions
[22]. At the same time, the polymer scaffold should
comprise good mechanical features to enable handling
in cell culture during transplantation. Finally, the
scaffold should be able to release growth factors, gene sig-
nals and other proteins, in a time-dependent manner. In
general, biomaterial scaffolds for tissue engineering and
regeneration can be divided into two categories: synthetic
or biologically derived natural materials. Synthetic
materials allow for precise control over properties such
as molecular weight of the polymer, degradation time,
mechanical properties and hydrophobic/hydrophilic
properties. However, they may not interact favourably
with cells as biologically derived materials do. The most
popular synthetic materials are the degradable polyesters
composed of lactide (PLA) and glycolide (PLG) and their
copolymers (PLGA). Mukherjee et al.[ 23] studied the
hydrophilic, biocompatible nanoﬁbrous scaffolds made
of poly(L-lactic acid)-co-poly(e-caprolactone) (PLACL)/
collagen that provides superior attachment and growth
of adult cardiac cells favouring native myocardium-like
alignment of newly seeded cardiac cells compared
with purely synthetic PLACL scaffolds. Moreover,
PLACL/collagen allows for cell–cell interaction without
attenuating the functional activity of cells and cardiac-
speciﬁc protein expression. These nanoﬁbrous scaffolds
have an elastic modulus of a magnitude nearing to that
of native heart tissue in cardiac tissue engineering.
3.2. Extracellular matrix in myocardium
The myocardial collagen matrix mainly consists of type
I and III collagens, which form a structural continuum.
Collagen type I ﬁbres mainly provide structural support
and give the heart properties that include stiffness and
resistance to deformation. The collagen type III ﬁbres
seem to play an important role as a link between con-
tractile elements of adjacent myocytes, carrying some
information useful for cell function. The lattice sur-
rounding the myocytes comprises a complex network
of structural proteins (collagen and elastic ﬁbres) and
adhesive proteins (ﬁbronectin and laminin) within a
hydrated proteoglycan and glycosaminoglycan-rich
milieu [24,25]. Collagens such as types I, III, IV, V, VI
and VIII have been identiﬁed in myocardium [26–28].
Cardiac ﬁbroblast-synthesized type I and III collagens
have different physical properties: type I collagen
mainly provides rigidity, whereas type III collagen
(a) (b)
µm
Figure 1. Nanoﬁbrous scaffolds for cardiac tissue engineering. (a) Electrospun collagen nanoﬁbres and (b) rat cardiomyocytes (CMs).
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jointly support and tether myocytes in maintaining
their alignment, tensile strength, shape and thickness
in order to prevent rupture and contribute to the pas-
sive and active stiffness of the myocardium [30].
Changes in collagen type I : III ratio within the heart
muscle may alter the tensile strength of the myocar-
dium. Experimental observations have shown that, in
the process of ischaemic heart disease, the myocardial
extracellular matrix (ECM) is deeply altered, and the
reserve of collagen type I, which is responsible for the
structural support, can decrease from 80 to 40 per
cent after MI [31]. A simultaneous increase in both
myocardial collagen and diastolic chamber stiffness
was attributed to increase the content of total
collagen [32].
Natural polymers include both ECM proteins and
derivatives (e.g. collagen) and materials derived from
plants and seaweed (alginate). Natural polymers
derived from ECM, such as Arg-Gly-Asp (RGD), col-
lagen, gelatin on their surfaces can facilitate cell
adhesion and maintain cell differentiation and advan-
tageous for tissue engineering applications. However,
these materials do not possess sufﬁcient mechanical
strength, unless they are chemically cross-linked to
degrade rather rapidly in the body. In addition,
batch-to-batch variations in material properties, as
well as potential contamination when the materials
are extracted from animal tissue, raise many concerns.
Recombinant forms of human collagen and other
materials are being produced, in order to avoid the
use of animal products, by expressing them in cell
lines including yeast [33]. Engineered heart constructs
must develop systolic (contractive) force with appropri-
ate compliance, and at the same time they must
withstand diastolic (expansive) loads. Chachques et al.
[22,34] performed clinical study in ischaemic patients,
showed that bone marrow cell therapy associated with
surgical implantation onto the epicardium of a cell-
seeded collagen matrix type I (MAGNUM) prevented
myocardial wall thinning, limited post-ischaemic remo-
delling and improved diastolic function. The use of
MAGNUM seems to create a microatmosphere where
exogenous and endogenous cells ﬁnd the optimal micro-
environment to repair with low scar formation. Cardiac
tissue engineering (collagen matrix seeded with stem
cells) emerges as a new therapeutic tool and extends
even more amazing possibilities of cell therapies in car-
diology, becoming a promising way for the creation of a
‘bioartiﬁcal myocardium’. Table 1 lists the mechanical
properties (stiffness and tensile strength) of heart
wall muscles and of the biomaterials investigated for
myocardial tissue engineering [35–49].
3.3. Strategies of biomaterials
Poly(glycerol sebacate) (PGS) scaffolds were tailored to
match the stiffness of heart muscle at the beginning of
diastole (stiffness is 10–20 kPa) or the stiffness at the
end of diastole (200–500 kPa) [50–52]. Once the
engineered tissue construct is placed in the body, vascu-
larization becomes a key issue for further remodelling in
the in vivo environment. The pore size in the range of
50–100 mm was sufﬁcient to allow vascularization of
the scaffold following transplantation [53]. Radisic &
Vunjak-Novakovic [54] suggested that larger
(100–300 mm) pore size is necessary for vascularization
and long-term survival of cardiac tissue constructs. The
large pores could impair vascularization because endo-
thelial cells are unable to bridge pores greater than a
cell diameter [55,56]. A potential approach to address
this problem is ﬁlling a highly porous scaffold with a
cell-seeded and/or gene-containing collagen gels for
vascularization [57,58]. Ott et al.[ 59] recently demon-
strated that decellularized adult rat hearts retaining
anisotropic structural and mechanical properties could
provide a scaffold for cultured neonatal rat heart cells
to regenerate nascent pump function of the engineered
bioartiﬁcial heart. Engelmayr et al.[ 60] fabricated
accordion-like honeycomb microstructure scaffold
(PGS) to demonstrate the novel ability to yield tissue-
engineered grafts with closely matched anisotropic
mechanical properties compared with right ventricular
myocardium of adult rats, while simultaneously
Table 1. Potential biomaterials for cardiac tissue engineering. PGA, (glycolic acid); PLLA, poly(L-lactic acid); PHB, poly-
(beta-hydroxybutyrate-co-betahydroxyvalerate); PPD, poly(para-dioxanone); TMC, 1,3-trimethylene carbonate; PDLLA,
poly(D,L-lactide); POC, poly(1,8-octanediol- co-citric acid); PGS, poly(glycerol sebacate). n.a. not applicable.
polymer
elastomer (E)/thermoplastic
(T)
Y modulus
(stiffness)
tensile
strength
degradation
(month) references
PGA T 7–10 GPa 70 MPa 2–12 [35,36]
PLLA T 1–4 GPa 30–80 MPa 2–12 [35]
PHB E 2–3 GPa 36 MPa degradable [37]
PPD or PDS E 0.6 GPa 12 MPa 6 [36,38]
TMC E 6 MPa 12 MPa degradable [38]
TMC-PDLLA (50: 50) E 16 MPa 10 MPa degradable [38]
POC T 1–16 MPa 6.7 MPa degradable [36,39]
PGS E 0.04–1.2 MPa 0.2–0.5 MPa degradable [36,40,41]
collagen ﬁbre (tendon–
bone)
E 2–46 MPa 1–7 MPa degradable [42,43]
collagen gel (calf skin) E 0.002–0.022 MPa 1–9 kPa degradable [44]
rat myocardium E 0.001–0.14 MPa 30–70 kPa n.a. [45–47]
human myocardium E 0.02–0.5 MPa 3–15 kPa n.a. [14,48,49]
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natal rat heart cells in the absence of external stimuli.
Currently, the conduits or patches are made of
Dacron polyester fabric, polytetraﬂuoroethylene
(PTFE), glutaraldehyde-treated bovine pericardium or
antibiotic preserved or cryopreserved homografts.
Ozawa et al.[ 61] studied non-biodegradable PTFE and
biodegradable non-woven PGA mesh, and biodegradable
poly-L-lactide knitted or woven fabric with 50 per cent
e-caprolactone and 50 per cent L-lactide spongy polymer
(PCLA) and transplanted the right ventricular outﬂow
tract. The unique structure of PCLA patch with a
spongy matrix favours in vivo cell colonization relative
to other patches and also offers advantages relative to
other biodegradable materials. Jin et al.[ 62]s t u d i e d
poly(lactide-co-e-caprolactone) served as a mechanical
ECM, where seeded bone marrow MSCs survived and
differentiated into CMs, ultimately regenerating the
myocardium and improving the cardiac function.
Zmora et al.[ 63] developed three-dimensional porous
scaffolds from alginate, using a simple, all-aqueous pro-
cess based on freeze-drying techniques. The scaffolds
were characterized by 90 per cent porosity and a pore
size of 50–150 mm, depending on the freezing regimen.
A more recent study shows the feasibility of bio-
engineering cardiac tissue within alginate scaffolds.
After implantation onto rat-infarcted myocardium, the
cardiac biografts stimulated intense neovascularization
from the neighbouring coronaries and attenuated left ven-
tricular dilatation and failure in an experimental model
[50–52]. Several type of approaches for the transplan-
tation of cell/biomaterials for MI and advantages/
disadvantages are presented in tables 2 and 3 [64–82].
4. POTENTIAL CELLS FOR MYOCARDIAL
TISSUE ENGINEERING
4.1. Cell function in myocardium
Cell therapy is a novel treatment to prevent ventricular
dilation and cardiac dysfunction inpatients suffered
from MI. Cell-based regenerative therapy is undergoing
experimental and clinical trials in cardiology, in order
to limit the consequences of decreased contractile
Table 2. Potential biomaterials and/or cell combinations used for cardiac tissue engineering. GAG, glycosoaminoglycan;
PLLA, poly(L-lactic acid); PCL, polycaprolactone; PGA, poly(glycolic acid); POC, poly(1,8-octanediol-co-citric acid).
polymer cells approach references
natural materials
collagen embryonic chick heart cells epicardial heart patch [64]
gelatin cardiomyocytes three-dimensional porous mesh [65]
collagen-GAG BM-MSCs three-dimensional porous mesh [66]
ﬁbrin glue no cells ventricular heart patch [67]
synthetic (degradable) materials
PLLA human ESC three-dimensional porous mesh [68]
PCL cardiomyocytes three-dimensional porous mesh [69]
PGA chondrocytes three-dimensional porous mesh [70]
polyurethane mouse ESC three-dimensional porous sponge [71]
PGS three-dimensional porous foam [72]
non-biodegradable materials
POC HL-1 (cardiac cells) scaffold application [73]
PTFE hUV ECs cardiovascular graft [74]
polypropylene no cells left ventricular constrain [75]
Table 3. Approaches for using myocardial tissue engineering.
approach advantages disadvantages reference
cellular cardiomyoplasty (injection
of cells only, direct/indirect)
minimal invasive lack of knowledge of cell function, cell loss,
effect to only endocardium
[76,77]
in situ engineering (injection of
cells and biomaterial)
biomaterial act as supporting
matrix while cells will
regenerate infarction
infancy stage [78,79]
injection of biomaterials alone matrix for homing autologous
progenitor cells
immunogenicity, as only natural polymers
have been suggested
[13]
left ventricular restraints
(wrapping up the ventricle with
biopolymer)
does not involve cell injection prevents remodelling but does not repair
damaged area
[80]
tissue engineering ensures cells are delivered to
desired area with minimal loss
involves open heart surgery, more work is
required to determine suitable cell type
and material
[81,82]
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following MI [3]. In cell-based therapy, isolated cell
suspensions are directly injected into injured heart via
pericardium, coronary arteries or endocardium. Direct
injection of isolated cells avoids open heart surgery.
However, it is difﬁcult to control the location of grafted
cells after transplantation. Cardiac myocytes are term-
inally differentiated cells with limited proliferative
capacity and cannot compensate cell loss that occurs
during MI or chronic heart failure. MI and heart failure
resemble the most prevalent pathologies. In either case,
the loss of CMs accounts for a decrease in myocardial
function which can lead to total organ failure or trigger
compensatory mechanisms such as hypertrophy of the
remaining myocardium. Adult stem cells are rare and
are technically difﬁcult to isolate because of a lack of
speciﬁc and accepted cell markers. Moreover, the pro-
cess of differentiating some cell types, such as human
embryonic stem cells, is difﬁcult to control and carry
the risk of teratoma. One exciting concept of a potential
endogenous cell source in the cardiovascular system is of
particular interest: the potential for ‘self-repair’ by
induction of hyperplastic growth [83].
A crucial aspect of cardiac tissue engineering is its
choice and the composition of cells in engineered
heart constructs. Proposed cell sources for cardiac
tissue engineering are provided in table 4 [84–97].
Clearly, cardiac myocytes have been the main cellular
component for the heart. However, can the heart func-
tion without non-cardiac myocytes? Endothelial cells,
ﬁbroblasts, smooth muscle cells, neural cells and leuco-
cytes comprise about 70 per cent of the total cell
number in working myocardium [98] and undoubtedly
play an important role in cardiac development and
function [99]. Endothelial cells (ECs) and smooth
muscle cells (SMCs), the main components of the vas-
culature, are not only necessary for transporting
nutrition and oxygen, but also secrete growth factors
and cytokines that are important for function of the
heart. Cardiac myocytes stimulate endothelial cell pro-
duction of platelet-derived growth factor-b (PDGF-b),
which combines with PDGF-a to induce endothelial
cell secretion of VEGF receptor Flk-1, which are critical
components of angiogenesis. Troponin-T is important
for effective CMs which contain contractile proteins as
it regulates the force and velocity of myocardial contrac-
tion, and actinin is an important constituent of the
contractile apparatus. Troponin-T is one of the essential
proteins for contractile function and an indicator of
differentiation in CMs. Nitric oxide secreted by endo-
thelial cells causes vasodilatation of coronary vessels,
exerts direct effects on myocardium and decreases iso-
tonic twitch shortening isolated myocytes and
enhances myocardial relaxation [100].
4.2. Mesenchymal stem cells
Stem cells seem to be the only meaningful cell source to
allocate enough myocytes for clinically relevant cardiac
tissue engineering in the future. One gram of adult myo-
cardium contains an estimated number of 20–40 million
myocytes [101] and a typical MI that induces heart failure
leads to a loss of approximately 50 g of the heart muscle
[102]. In order to compensate such a loss, it seems likely
that those engineered myocardium not only have a simi-
lar size but also contain equal amount of myocytes (50 g
approx. 1–2 billion). CMs have the native contractile and
electrophysiologicalpropertiesoftheheartmuscle;theyare
difﬁcult to obtain, expand and are allogenic cells. Disad-
vantages of embryonic stem cells include their potential
for transformation into teratocarcinoma and other malig-
nancies. In contrast, MSCs can easily be isolated from
bone marrow, cultured, non-immunogenic and can readily
be expanded in the laboratory, making them an attractive
cell source for cardiac tissue engineering. MSCs have the
greatest potential for use in cell-based therapy of human
heart diseases, especially in MIs. The therapeutic potential
of MSCs in myocardial repair is based on their ability to
directly differentiate into cardiac tissues and on paracrine
actions of factors released from them. However, the major
obstacle in the clinical applications of MSC-based therapy
is the poor viability of transplanted cells owing to harsh
microenvironment-like ischaemia, inﬂammation and/or
anoikis in the infarcted myocardium. Katritsis et al.[ 103]
proved that intracoronary-treated MSCs reduced infarct
size in human patients compared with controls. These
results demonstrate the safety and feasibility of intra-
coronary MSC infusion in post-MI patients. Moreover, it
seems that intra-myocardial delivery of MSCs during cor-
onary bypass grafting and via catheter-based delivery
system also is safe and feasible [104]. Therefore, MSCs
may be used as a novel agent to induce regeneration and
protection of infarcted myocardium.
Hareetal.[105]observedspeciﬁcsafetymonitoringindi-
cated that cell-treated patients have improved outcomes
with regard to cardiac arrhythmias, pulmonary function,
left ventricular function and symptomatic global assess-
ment. These ﬁndings support the conduct of more
extensive studies assessing the value of allogenic hMSCs
for the treatment of cardiovascular disorders. Chen et al.
[106] conducted a randomized study to investigate the
effectiveness of intracoronary injection of MSCs in patients
with acute MI. After occlusion of the infarct-related coron-
ary artery, a suspension of autologous MSCs was directly
injected into the target coronary artery through an
inﬂated, over-the-wire balloon catheter. Cardiographic
evaluation demonstrated signiﬁcant variation in the
Table 4. Potential cells sources for myocardial tissue
engineering.
source reference
skeletal myoblasts [84]
crude bone marrow [85]
endothelial progenitor cells [86]
haematopoietic stem cells [87,88]
mesenchymal stem cells [89]
smooth muscle cells [90]
umbilical cord cells [91]
ﬁbroblasts [92]
human embryonic stem cells [93]
foetal cardiomyocytes [65,83]
myocardial progenitors [94–96]
cloned cells [97]
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controls. The percentage of hypokinetic, akinetic and dys-
kinetic segments decreased in treated patients, while wall
movement velocity over the infarcted region and left-ven-
tricular ejection increased signiﬁcantly in the MSC-
treated group. Engrafted cells expressed the CM marker
proteins, such as b-myosin heavy chain, a-actinin, cardiac
troponin-T and phospholamban. Furthermore, engrafted
cells develop into myoﬁbres containing striated sarcomeric
myosin heavy chain and cell-to-cell junctions. Cellular car-
diomyoplasty using needle injections is emerging as a
treatment option for individuals with chronic heart failure,
but it may be limited by failure to regenerate cardiac mass
in cardiac tissue engineering (CTE).
Miyahara et al.[ 107] developed cell sheets using
temperature-responsive culture dishes to reverse car-
diac wall thinning and prolong survival after MI,
primarily owing to growth factor-mediated paracrine
effects and by decreasing left ventricle wall stress
after transplantation of cell sheets. These cell sheets
allow cell–cell connections and maintain the presence
of adhesion proteins because enzymatic digestion is
not needed (ﬁgure 2). Placement of the adipose-
derived MSC (ADMSC) sheets onto a scarred myocar-
dium in rats resulted in diminished scarring and
enhanced cardiac structure and function. Therefore,
cell sheet transplantation may be a promising strategy
for partial cardiac tissue reconstruction. In addition,
owing to the increased secretion of angiogenic growth
factors, VEGF, PDGF, basic Fibroblast growth
factor (bFGF) and hepatocyte growth factor (HGF),
the cardiac cell sheets containing ECs appeared to
possess a signiﬁcant innate potential for neovasculari-
zation even before transplantation for MI. Chachques
et al.[ 108] suggested that cell transplantation offers
promises induce angiogenesis, and to restore myocar-
dial viability and regional ventricular function,
therefore limiting remodelling for patients who have
had a non-massive MI and probably for patients
presenting with non-ischaemic dilated cardiomyopathy.
4.3. Bone marrow-derived cells
Experimental studies have shown that bone marrow-
derived cells are capable of regenerating infarcted myo-
cardium and inducing myogenesis and angiogenesis,
which leads in turn to amelioration of cardiac function
in mice and pigs [109,110]. Capsi & Gepstein [111]h a v e
given an excellently tabulated overview on the clinical
trial results of using bone marrow stem cells in the
treatment of acute and chronic heart diseases. Studies
in animal models of ischaemia and phase I and II clini-
cal trials suggested that delivery of haematopoietic stem
cells (HSCs) and circulating endothelial progenitor
cells, both originating from bone marrow stem cells,
may result in the improvement of the ventricular func-
tion in ischaemic heart disease patients. Kocher et al.
[109] demonstrated that an intravenous injection of
human bone marrow donor cells into infarcted myo-
cardium of rats resulted in a signiﬁcant increase in
neovascularization of post-infarction myocardial
tissue, attenuation of CMs apoptosis and left ventricu-
lar remodelling. Strauer et al.[ 77] transplanted bone
marrow cells (BMCs) directly into the infarcted zone
(a) (b)
(c) (d)
Figure 2. Preparation of monolayered mesenchymal stem cells (MSCs). (a) MSCs 2 days after seeding on a temperature-respon-
sive dish, (b) cultured MSCs expanded to conﬂuence within the square area of the dish by day 3, (c) the monolayered MSCs
detached easily from the culture dish at 208C and (d) the completely detached monolayered MSCs were identiﬁed as a 12  
12 mm square sheet [107].
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of a balloon catheter, which was placed within the
infarct-related artery. At this time, intracoronary cell
transplantation via balloon catheter was performed,
using six to seven fractional high-pressure infusions
of 2–3 ml cell suspension, each of which contained
1.5–4   10
6 mononuclear cells (ﬁgure 3). The results
of the cell therapy group showed considerable
improvement in left ventricular function. The
transplantation of autologous BMCs as well as intracor-
onary approach represents a novel and effective
procedure for the repair of infarcted myocardium [112].
4.4. Cardiomyocytes
CMs have contractile and electrophysiological pro-
perties of the heart muscle, and they are difﬁcult to
obtain and expand for transplantation. CM sheets
transplanted into ischaemic hearts were able to improve
cardiac function and also bridged to form morphologi-
cal communication through functional gap junctions
within intact areas of the damaged myocardium [113].
Itabashi et al.[ 114] produced temperature-sensitive,
resin-coated culture dishes to improve the clinical appli-
cability of CM transplantation. The surface of these
dishes became hydrophilic, when the temperature is
lowered, and cultured CMs can be peeled off in sheets.
Using this approach, a thin ﬁbrin polymer membrane
on the surface of culture dish is generated by reacting
ﬁxed concentrations of ﬁbrinogen and thrombin.
When CMs are cultured on these dishes, they secrete
a variety of endogenous proteases that break down
ﬁbrin polymer membrane in approximately 3 days,
making it possible to obtain CM sheets which are
characterized by good cell viability and residence
rates. Most studies report that less than 10 per cent
CMs transplanted using a syringe resides stably in the
heart, whereas few cells are lost after transplantation
in which the CM sheets are transplanted subcu-
taneously. A further advantage of using CM sheets is
that they can be layered to varying tissue thicknesses.
These ﬁndings support that myocardial sheet formation
is an important tool in future cell transplantation
technology [115]. Zimmermann and co-workers
[116,117] have developed a three-dimensional heart
tissue model using a collagen matrix that allowed
direct measurement of isometric contractile forces.
Zimmermann et al.[ 57,58] developed a methodology to
create engineered heart tissue (EHT) from neonatal rat
heart cells. EHTs differ from classical scaffold-based
tissue-engineered cardiac constructs in that they are orig-
inally made from heart cells, liquid collagen type I and
Matrigel as well as growth supplements, reconstituted
in circular moulds and subjected to mechanical strain
(ﬁgure 4). Under these conditions, cardiac organoids
develop spontaneously and show contractile as well as
electrophysiological properties of working myocardium.
The ﬁrst EHT graft implantation experiments in healthy
rats showed survival, strong vascularization and a sign of
terminal differentiation to support contractile function of
the infarcted heart.
4.5. Skeletal myoblasts
Cell transplantation for cardiac support and regener-
ation may repair the injured heart but is limited by
poor effect in systolic function. This can be due to the
lack of gap junctions between the native myocardium
and the grafted cells. Myocardial injection of autolo-
gous myoblasts has been clinically performed and
shown to produce some limited recovery from heart dys-
function. In these therapies using direct delivery of
isolated cells, each cell differentiates and remodels in
response to its surrounding environment, leading to
tissue regeneration and functional repair. Today, the
most widely used cell types for cardiac cell therapy in
human patients are skeletal muscle-derived progenitors
or myoblasts, and crude bone marrow mononuclear cells
[118]. These cell types share advantages over other cells
proposed for cardiac repair in that they are readily
available, autologous and could be expanded in vitro.
Layered skeletal myoblast sheets also provide improved
left ventricular contraction, reduced ﬁbrosis and pre-
vented remodelling through recruitment of HSCs and
the release of various growth factors [119]. Skeletal
myoblasts do not fully differentiate into CMs in vivo
RCA LCX
syringe containing
adult stem cells
border zone
balloon catheter
LAD
cell flow into the
infarcted area
migration into the
central necrosis
Figure 3. Transplantation of bone marrow cells into infarcted myocardium in humans. The balloon catheter enters the
infarct-related artery and is placed above the border zone of the infarction. The catheter is then inﬂated and the cell suspension
(including the patient’s own cytokines) is infused at high pressure under stop-ﬂow conditions. In this way, cells are transplanted
into the infarcted zone through the infarct-related vessel system. Cells and cytokines inﬁltrate the infarcted zone. The arrows
show the possible route of cell migration and cytokine inﬁltration. LAD, left anterior descending coronary artery; LCX, left
circumﬂex artery; RCA, right coronary artery [112].
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myotubules do not operate in synchrony with the sur-
rounding myocardium [120]. This is due, to the least
part, to a lack of connexin activity and electrical coup-
ling with the surrounding myocardial cells. Animal
experiments also showed that the electrical coupling
of skeletal myoblasts to resident CMs is increased
when the skeletal cells are induced to overexpress con-
nexin 43, indicating that there might be ways to
overcome the arrhythmogenic obstacles [121]. The
association of electrostimulation with cellular cardio-
myoplasty could be a way to transform passive cell
therapy into ‘dynamic cellular support’. The principle
of electrophysiologic conditioning of skeletal muscle
ﬁbres (developed for dynamic cardiomyoplasty pro-
cedure) can be applied in cellular cardiomyoplasty
[122]. Electrostimulation of both ventricles following
skeletal myoblast implantation seems to induce the
contraction of the transplanted cells and a higher
expression of slow myosin, which is better adapted for
chronic ventricular assistance. Patients with heart fail-
ure presenting myocardial infarct scars and indication
of cardiac resynchronization therapy might beneﬁt
from simultaneous cardiac pacing and cell therapy
[123]. The occurrences of ventricular perforation
during intramyocardial transcatheter injection of
myoblasts into thinned myocardium can be 5–7 mm;
therefore, experience with intracardiac injection is criti-
cal for reducing complications. Autologous myoblast
transplantation has the capacity to replace lost myocar-
dial contractile cells and reverse the ventricular dilation
[124,125]. Dib et al.[ 126] investigated the feasibility and
safety of injecting myoblasts into a chronic myocardial
infarct that can be thin, difﬁcult to penetrate and
potentially easy to perforate. Myoblasts can be safely
and feasibly administered in patients by transcatheter
technique in the hands of a trained investigator.
Larger, randomized, double-blind, placebo-controlled
and multi-centre clinical trials are warranted to further
test this therapeutic approach for myocardial tissue
engineering (MTE).
4.6. Umbilical cord blood stem cells
Human umbilical cord blood-derived stem cells
(HUCBCs) might solve the problem of impaired stem
cell function and number of sick and aged population.
A speciﬁc advantage of HUCBCs is the immature
immunogenicity of the mononuclear fraction, which sig-
niﬁcantly reduces the risk of rejection by host [83].
HUCBCs contain relatively high numbers of CD133
þ
and CD34
þ progenitor cells. These cells have homing,
myogenic and angiogenic potential that are relevant
for myocardial repair [127]. The therapeutic effect of
HUCBCs has been demonstrated in animal models of
hind limb ischaemia and stroke [128,129]. The use of
HUCB stem cells to repair the infarcted myocardium
might be of importance for elderly people in whom
the availability of autologous stem cells is limited for
cell therapy. Intramyocardial injection of HUCBCs
preserves LV function following infarction. The use of
a cell-seeded collagen matrix combined with cell injec-
tion prevents ventricular wall thinning and limits
post-ischaemic remodelling. This tissue engineering
approach seems to improve the efﬁciencyof cellularcardio-
myoplasty and could emerge as a new therapeutic tool for
the prevention of adverse remodelling and progressive
heart failure [130]. Improved methods for stem cell
(a) (b)
(c) (d)
Figure 4. Construction of optimized engineered heart tissue (EHT). Stacking ﬁve single EHTs, (a) resulting in synchronously
contracting multi-loop EHTs, (b) ready for in vivo engraftment, (c,d) six single-knot sutures served to ﬁx multi-loop EHTs on
the recipient’s heart [57,58].
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would increase the prospect of using HUCB cells to treat
MI patients, especially those who need it urgently.
4.7. Adipose-derived stem cells
Fat is abundant in most individuals, allowing a simpler
and more efﬁcient harvesting, as adipose tissue has a
higher stem cell yield than bone marrow [131], and
diminishing the need of in vitro expansion. Adipose-
derived stem cells (ADSCs) can easily be isolated and
cultured ex vivo and express markers associated with
mesenchymal and perivascular cells including STRO-1,
CD146 and 3G5, maintaining their characteristic multi-
potency to differentiate into chondrocytes, osteoblasts,
endothelial cells and CMs. The differentiation capacity
and paracrine activity of these cells made them an opti-
mal candidate for the treatment of a diverse range of
diseases from immunological disorders as graft versus
host disease to cardiovascular pathologies peripheral
ischaemia [132]. Four different possible fates of ADSCs
are described by Choi et al.[ 133] such as: (i) differentiat-
ing into cardiac muscles by direct contact with adjacent
rCM; (ii) differentiating into SMCs that have migrated
to and surrounded immature vessels; (iii) adipogenic
differentiation; and (iv) secreting proangiogenic factors
to recruit endogenous endothelial cells. In general, trans-
planted cells can act upon the damaged heart in several
ways, such as increasing myocardial perfusion, enhancing
endogenous cell survival, attracting progenitors and reg-
ulating tissue ﬁbrosis. Rigol et al. [134], studied a pig
model of ischaemia reperfusion, injected passage three
ADSC either via a transendocardial catheter or through
intracoronary infusion one week after infusion of MI.
Transplanted cells engrafted, differentiated to smooth
muscle cells and increased the density of arterioles to a
similar degree by either approach, although they were
not able to demonstrate signiﬁcant cardiac function.
Okura et al.[ 135] showed that the phenotype of
hADMSCs could be changed to cardiac-like cells
(CLCs) by the induction of dimethylsulphoxide. These
hADMSCs-derived CLCs engrafted into a scarred myo-
cardium and differentiated into CMs for cardiac tissue
regeneration. Hypoxia-treated ADSC co-culture with
early postnatal CMs (2–5 days) have been shown to
enhance blood vessel growth not only by the production
of paracrine factors, but also by promoting the differen-
tiation of existing cardiac progenitor cells to endothelial
cells [136,137]. The different cell sources, principally skel-
etal myoblasts, ADSCs and BMCs, should provide the
angiogenic and ventricular remodelling in myocardial
regeneration.
5. BIOMATERIAL STRATEGIES FOR
ALLEVIATION OF MYOCARDIAL
INFARCTION
Several groups have reported encouraging results with
various techniques to construct beating cardiac patches
for transplantation. However, assembling vascularized
three-dimensional myocardial tissues remains an enor-
mous challenge. Most studies support the notion that
cell implantation in models of MI can improve contractile
and mostly diastolic function. Presently, clinical studies
are underway to investigate the feasibility of cell implan-
tation in patients for MI. An alternative approach for the
injection or infusion of isolated cells into heart is the
design of artiﬁcial cardiac muscle constructs in vitro for
later implantation in vivo. Several principally different
cardiac tissue engineering approaches have been devel-
oped. These are: (i) seeding of CMs on preformed
polymeric scaffolds, which may function as organ blue-
prints, (ii) stacking of CMs monolayers to form cardiac
muscle-like tissue without additional matrix material,
and (iii) entrapping of CMs in a cardiogenic environment
to support self-assembly into functional myocardium.
These tissue engineering concepts have been tested in
animal models showing survival and growth of engrafted
heart muscle surrogates [120].
Restoration of heart function by replacement of
diseased myocardium with functional CMs is an intri-
guing strategy because it offers a potential cure [138].
Shimizu et al.[ 139] cultured CMs on temperature-
responsive polymer poly(N-isopropylacrylamide)
(PIPPAm) by electron beam exposure, producing
surfaces that are slightly hydrophobic and cell-
adhesive under culture condition at 378Ca n dc h a n g e
reversibly to hydrophilic and non-cell-adhesive below
328C owing to rapid hydration and swelling of grafted
PIPPAm. This unique surface change allows for cul-
tured cells to detach spontaneously from these
grafted surfaces simply by reducing culture tempera-
ture. The CM sheets, which readily detach from
PIPPAm-grafted surfaces and transfer onto rigid cul-
ture surfaces or other CM sheets, stop their intrinsic
beating temporarily but spontaneously recover
withinafewdays.Thecellsheetmanipulationtechnol-
ogy (cell sheet engineering) using temperature-
responsive cell culture surfaces has been shown to be
very useful for fabricating electrically communicative,
pulsatile cardiac grafts both in vitro and in vivo.T h i s
technology should have enormous potential for con-
structing in vitro three-dimensional heart tissue
models and for improving viable functional graft
materials for clinical tissue repair. Synthetic polymers
are essential materials for tissue engineering not only
owing to their excellent processing characteristics,
which can ensure off-the-shelf availability, but also
advantages of biocompatible and biodegradable prop-
erties. These polymers have predictable and
reproducible mechanical and physical properties (e.g.
tensile strength, elastic modulus and degradation
rate), and can be manufactured with great precision.
Degradability is generally a desired characteristic in
tissue engineering substrates because the second sur-
gery to remove them (such as a heart patch) would
be averted if the substrate could be removed by physio-
logical system of the host body. The elastomer PGS,
recently developed for soft tissue engineering, rep-
resents a feasible candidate that fulﬁls all of the
above criteria for cardiac tissue engineering [140].
Elastomer-based grafts may facilitate compliance of
matching, thereby ameliorating the lifespan of the
patients. Scaffolds composed of PGS are elastic and
reversibly deformable and are thereby conducive to
contracting CMs and engineered myocardium [41].
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mechanical properties, the capacity to form a variety
of geometries on the macro- and micro-scales, and
low inﬂammatory response and ﬁbrotic encapsulation,
coupled with retention of mechanical strength during
degradation in vivo. NUSNNI Laboratory fabricated
PGS/gelatin core/shell ﬁbres by coaxial electrospin-
ning for cardiac tissue engineering. In PGS/gelatin
core/shell ﬁbres, PGS is used as a core polymer to
impart the mechanical properties and gelatin as a
shell material to achieve favourable cell adhesion and
proliferation [141]. The expression of MSC-speciﬁc
marker protein CD 105 by the MSCs cultured in the
co-culture (MSC/CM) environment on TCP, gelatin
and poly(glycerol sebacate)/gelatin core/shell ﬁbres
(ﬁgure 5a,d,g). Figure 5b,e,h shows the expression of
cardiac marker protein actinin. MSCs differentiate
into cardiogenic lineage to express both CD 105 and
cardiac-speciﬁc marker protein actinin. Dual
expressionofCD105andactininbyMSCsaftercardio-
genic differentiation is observed in ﬁgure 5c,f,i.I n
PGS/gelatin core/shell ﬁbres (ﬁgure 5i), more cells
express actinin markers indicating that the differen-
tiation is higher in these scaffolds than in gelatin
nanoﬁbres (ﬁgure 5f ). The observed results proved
that the PGS/gelatin core/shell ﬁbres have potential
biocompatibility and mechanical properties for
fabricating nanoﬁbrous cardiac patch and would be a
prognosticating device for the restoration of
myocardium.
Many studies have been published using different
synthetic or naturally occurring biomaterials for the
application in MTE. Among the natural polymers, col-
lagen, alginate and gelatin have been under intensive
investigation for MTE by research groups in Germany
[107,110], and Israel [63,83,142], respectively. Among
the synthetic polymers, PGA, and copolymers with
poly(lactic acid) (PLA) and poly(e-caprolactone)
(PCL) have been studied systematically using bioreactors
for MTE at MIT [143,144] and Harvard [145,146]. The
thermo-responsive polymer PIPAAm was applied to car-
diac tissue engineering by researchers in Japan [147].
Cardiac devices made from non-degradable polymers
have been under intensive animal and human trials by
surgeons mainly from the USA [148,149]. Seikiya et al.
[150] attempted to control the vascularization processes
in vitro to create thicker functional tissues. When ECs
were co-cultured within cardiac cell sheets, angiogen-
esis-related gene expression and the formation of EC
networks were observed in vitro. The EC networks
were maintained within the cell sheets after harvest
from temperature-responsive culture dishes and matured
to form tubularized vascular networks after in vivo trans-
plantation. The formation of myocardial tubes with
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 5. Core/shell (PGS/gelatin) ﬁbrous structure for regeneration of myocardial infarction (MI). Dual immunocytochemical
analysis for (a,d,g) the expression of MSC marker protein CD 105 and (b,e,h) cardiac marker protein actinin in the co-culture
samples and (c, f, i) the merged image showing the dual expression of both CD 105 and actinin; on (a,b,c) the TCP, (d,e,f) gelatin
nanoﬁbres and (g,h,i) PGS/gelatin core/shell ﬁbres at 60  magniﬁcation. Nucleus stained with DAPI [141].
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sheet engineering. These new myocardial structures pre-
sent a possible core technology for the creation of
engineered tissues capable of acting as independent
cardiac-assisting devices for CTE. Narmoneva et al.
[151] observed that the presence of EC networks pro-
foundly improves CM survival and organization by
maintaining a minimum intercapillary distance to pro-
vide oxygen and nutrients. Therefore, the presence of
ECs may be directly correlated with CM function.
Chen et al.[ 50–52] demonstrated that the porous
tissue scaffold sandwiched with multi-layered sheets of
MSCs serve as an effective cardiac patch to restore
the dilated LV and improve heart functions in a syn-
geneic rat model with an experimentally chronic MI.
Cells derived from rat ventricular muscle seeded into a
biodegradable gelatin mesh (Gelfoam) can grow in
three dimensions, proliferating to form cardiac-like
tissue. Gelatin grafts persisted over a ﬁve week course
after implantation either into the subcutaneous tissue
or onto the myocardial scar of adult rats. These grafts
maintained spontaneous and rhythmic contractility,
but the effect of this graft on ventricular function
after myocardial scarring remains uncertain. Matrigel
constructs seeded in perfusion had physiologically
high and spatially uniform cell density throughout the
perfused construct volume, whereas constructs seeded
in dishes had most cells located approximately
100 mm thick layers at the top surface. Cultured cells
expressing cardiac-speciﬁc differentiation markers (sar-
comeric a-actin, sarcomeric tropomyosin and cardiac
troponin) were present throughout the perfused con-
structs and only within a approximately 100 mm thick
surface layer in dish-grown construct [152]. Koﬁdis
et al.[ 153] engineered a novel and promising type of
myocardium-like tissue that resembles native cardiac
muscle in many aspects. In addition, artiﬁcial myocar-
dial tissues (AMTs) might serve as a basis for the
development of tissue, which is capable of replacing
human myocardium in many disease states of the failing
heart. The ﬁgure 6 shows schematic diagram of the
future progress in stem cell technology, as well as dis-
covery of factors responsible for proliferation of MSCs
and adult CMs, and when combined with suitable tech-
niques of gene transfer might allow for the production of
autologous artiﬁcial myocardium-like tissue/injectables
capable of correcting infarcted myocardium and
restoring impaired heart function. Finally, vasculariza-
tion of in vitro-engineered tissues might result in the
generation of a complete bioartiﬁcial heart.
5.1. Bioreactor system
A bioreactor provides a controllable biochemical and
biophysical environment during the culture of engineer-
ing tissues. Compared with static culture, bioreactors
enable control and monitoring of mass transport of
oxygen, growth factors and nutrients, and biophysical
stimuli such as cyclic stretch, hydrodynamic forces
and electrical stimulations. These stimuli have shown
to improve homogeneity of the construct, enhance the
production of ECM components and to improve the
growth factors active cellular
construct
catheter based
delivery
injection
infarcted myocardium
restored functional
activity of heart
right
coronary
artery
left coronary
artery
anterior
interventricular
artery
biomaterial
strategy
stem
cells
in vitro culture
system
in vivo system
Figure 6. Schematic of the regeneration of MI.
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bioreactor provided pulsatile ﬂow physiologically rel-
evant shear stresses and the ﬂow rate was constructed
by the incorporation of a normally closed solenoid
valve that was driven to open at a frequency of 1 Hz
at the output from the perfusion chamber. Cultivation
under pulsatile ﬂow enhanced contractile properties of
the cardiac constructs in bioreactor system [155].
Akins et al.[ 156] have shown three-dimensional
contractile CM aggregates on polystyrene beads in a
rotating bioreactor system. Papadaki et al.[ 157] engin-
eered three-dimensional cardiac constructs for in vitro
impulse propagation studies using biodegradable poly-
mer (PGA) scaffolds in rotating bioreactor systems. Li
et al.[ 158] have demonstrated that tissue-engineered
cardiac graft transplantation using biodegradable gela-
tin mesh replaced both myocardial scar and right
ventricular outﬂow track defects.
5.2. Injectable biomaterials
Recently, injectable tissue engineering scaffolds have
been constantly pursued, aiming at minimally invasive
surgery. Alginate, a negatively charged polysaccharide
from seaweed that forms hydrogels in the presence of
calcium ions, is being developed for tissue engineering
in native and modiﬁed forms for cardiac tissue engineer-
ing. Compared with other materials, a major advantage
of the injectable alginate biomaterial solution is its
non-thrombogenicity. Tsur-Gang et al.[ 159] recently
showed that a solution of calcium cross-linked alginate
biomaterial with cell adhesion peptides, containing
the sequences RGD and YIGSR, or a non-speciﬁc pep-
tide (RGD), can be injected via a needle into the
infarct, where it undergoes phase transition into
hydrogel for left ventricular remodelling and function
of post-MI. This alginate hydrogel implant provides
temporary physical support to the damaged cardiac
tissue by replacing some of the functions of damaged
ECM while preventing adverse cardiac remodelling
and dysfunction after recent and old MI in rat. With
time, the dissolvable hydrogel gradually disappears,
and water-soluble alginate chains are evacuated and
excreted by the kidneys. The injectable biomaterial is
delivered into the infarct zone. Christman et al.[ 78]
ﬁrst demonstrated improved cell survival when trans-
planted cells delivered in an injectable scaffold were
compared with the typical cellular cardiomyoplasty
technique. The injectable polymer ﬁbrin glue was also
shown to induce neovascularization within the ischae-
mic myocardium and to reduce infarct expansion.
More interesting is the observation that injection of
ﬁbrin glue with or without skeletal myoblast preserved
LV geometry and cardiac function in an acute MI model
[79]. Anatomically, injectable gels have been applied as
an endoventricular heart patch. It has been shown that
injection of ﬁbrin glue preserves left ventricular geome-
try and prevents a deterioration of cardiac function
following MI [153]. The injectable gels lack sufﬁcient
stiffness for the application in human tissues. The
stiffness of a variety of possible materials is in the
range of 10 Pa to 20 kPa, such as ﬁbrin (approx.
50 Pa), Matrigel (30–120 Pa), type I collagen gels
(100 Pa to 6 kPa for 1–3 mg ml
21)[ 152,153], polyethy-
lene glycol (1–3 kPa) [160] and alginate (100 Pa to
6k P a ) [ 159]. Injectable biomaterials can reduce wall
stress by increasing the scar thickness and stabilizing
the chamber size [161]. The injectable alginate increases
scar thickness and provides physical support for
improved healing and repair. The ability to deliver bio-
material into the infarct by intracoronary injection can
revolutionize patient treatment after MI and could
prevent mechanical complications, heart failure and
death [162]. These materials are softer than human
heart muscles at the end of diastole, the stiffness of
which is approximately 50 kPa in normal hearts or
200–300 kPa in CHF hearts. Hence, it is unlikely that
they could provide sufﬁcient mechanical support to
the diseased heart. In future, modifying the hydrogel
with biopolymers and growth factors to increase the
mechanical properties and having potential elastic
properties suitable for cardiac tissue engineering could
be possible.
5.3. Cardiac supporting devices
MI is caused by a signiﬁcant reduction in coronary
blood supply to an area of the heart over a sustained
period, eventually forming non-contractile ability com-
pared with the healthy heart. Representative cardiac
restraint devices include Marlex mesh (polypropylene)
[163], Merselene mesh (knitted polyester) [164],
BioVAD [165] and MAGNUM [34]. A commercially
available cardiac support device from Acorn Cardiovas-
cular Inc. (knitted polyester) manufactured from a very
common polymer PTFE has been used as a wrap
around the cardiac ventricle. Several issues still need
to be addressed for the success of MTE. First, electrical
coupling between the cells is required, in order to ensure
that cells on the graft or patch beat in synchrony.
Second, electrical coupling between the construct and
native myocardium for simultaneous beating is still of
concern. It has been reported that cell sheet engineering
has overcome this problem, where graft integration and
no arrhythmias were reported [166–168]. MTE will
hopefully lead to improvement in function of the dis-
eased myocardium as it integrates with the heart,
reducing the morbidity and mortality of patients with
heart failure [169].
6. CONCLUSIONS
Cardiovascular tissue being a hierarchically organized
tissue, the delivery of cytokines and bioactive proteins
in a controlled and timely manner through nanostruc-
tured materials with suitable mechanical properties
could be the ideal approach for improving the cardiac
function. The three established mechanisms involved
in myocardial repair are the CM regeneration, vasculo-
genesis and paracrine actions. Cardiac functional
improvement can be accomplished using growth factors
such as VEGF, which can mediate the angiogenic effect,
and IGF-1, which can mediate the apoptotic effect.
Even embryonic stem cells could be differentiated into
CMs by cardiac paracrine pathways mediated through
TGF-b and BMP-2, and patients beneﬁt after its
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platforms that combine both ‘smart’ biomaterials and
stem cells can provide the necessary stimulatory effects
for differentiation of stem cells into CMs. At the same
time, the encouraging preliminary results of cardiac
tissue engineering experiments in small animal models
helped in widening new theories of myocardial tissue
regeneration. Material development involving injectable
polymeric hydrogels and matrices compatible for cath-
eter delivery allows for the establishment of cellular
environments more suitable for cardiac regeneration.
For tissue engineering technology to be more effective
in human patients, it is critical that we can create
1c m
2 muscular patch/device to repair infarct myocar-
dium. CMs are very sensitive to prolonged ischaemia
and may respond in necrosis and apoptosis of the engin-
eered myocardial graft. In coming years, scientists and
engineers will bring about new insights into this fasci-
nating ﬁeld and hopefully answer questions regarding
the optimal scaffold, a cell source that is autologous
and unlimited, optimized methods to generate large
tissue constructs with relevant contractile properties
and eventually surgical techniques to replace or substi-
tute diseased myocardium with engineered cardiac
muscle constructs. The rapid innovations in tissue
engineering research and stem cell biology will acceler-
ate and optimize engineered tissue assembly; they
may bring us to the point of being able to create an
alternative tissue/injectables to repair or replace
damaged heart muscle for the alleviation of MI.
This study was supported by NRF-Technion grant (R-398-001-
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